Logo Image
|Articles|January 15, 2003

BioPharm International

  • BioPharm International-01-01-2003
  • Volume 16
  • Issue 1

Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 2, Implementation Strategies

by S. Alison Arnold, Linda M. Harvey, and Brian McNeil, Strathclyde Fermentation Centre (Scotland), and Jeffrey W. Hall, FOSS NIRSystems Timely process information is required to make effective fermentation decisions, but those data are rarely available. NIR spectroscopy can allow you ? by incorporating rapid, nondestructive, multiconstituent analyses of fermentation broth directly into fermentation control strategies ? to make those decisions. This article will help you make that improvement by outlining the analysis strategies.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 24 years ago

Virus Inactivation in the 1990s and into the 21st Century: Part 4, Culture Media, Biotechnology Products, and Vaccines

almost 24 years ago

Biotech World: Canada's Supreme Court says "No" to Harvard Mouse

almost 24 years ago

Rethinking the Economics of Chromatography: New Technologies and Hidden Costs

almost 24 years ago

Outsourcing Outlook: Using Virtual Private Networks to Gain Competitive Advantage

almost 24 years ago

Inside Washington: Coverage and Consolidation ? Key Issues for Biotech Companies

almost 24 years ago

Guest Editorial: At the Governance Crossroad

almost 24 years ago

Reducing Costs by Facility Design

almost 24 years ago

Guidelines for Optimization and Scale-Up in Preparative Chromatography

almost 24 years ago

Analytical Advances: Funneling a Flood Tide of Data ? New Software Accelerates Bioinformatic Analyses

almost 24 years ago

Survival Strategies: Board Compensation Changing with the Times

Related to this article

View more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more